Detalles de la búsqueda
1.
Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes.
Diabetes Obes Metab
; 20(2): 419-426, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28817248
2.
Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus.
Diabetes Obes Metab
; 20(5): 1193-1201, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29316143
3.
Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes.
Diabetes Obes Metab
; 19(8): 1071-1077, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28191913
4.
Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes.
Diabetes Obes Metab
; 19(11): 1521-1528, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28371155
5.
Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.
Diabetes Obes Metab
; 19(4): 482-488, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-27888561
6.
Population pharmacokinetics and pharmacodynamics of nasal glucagon in patients with type 1 or 2 diabetes.
CPT Pharmacometrics Syst Pharmacol
; 2024 May 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38736200
7.
Dose Rationale of Nasal Glucagon in Japanese Pediatric Patients with Diabetes Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation.
Paediatr Drugs
; 25(3): 377-387, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36973474
8.
Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes.
J Diabetes Sci Technol
; 17(2): 274-282, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36575993
9.
Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval-An Industry Perspective.
Clin Pharmacol Ther
; 114(4): 751-767, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37393555
10.
Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist.
Cell Metab
; 35(2): 274-286.e10, 2023 02 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36630958
11.
Optimization of trial duration to predict long-term HbA1c change with therapy: A pharmacometrics simulation-based evaluation.
CPT Pharmacometrics Syst Pharmacol
; 11(11): 1443-1457, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35899461
12.
Development and Verification of a Body Weight-Directed Disease Trial Model for Glucose Homeostasis.
J Clin Pharmacol
; 61(2): 234-243, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32895980
13.
Insulin, Not the Preservative m-cresol, Instigates Loss of Infusion Site Patency Over Extended Durations of CSII in Diabetic Swine.
J Pharm Sci
; 110(3): 1418-1426, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33321138
14.
Development and Qualification of a Drug-Disease Modeling Platform to Characterize Clinically Relevant Endpoints in Type 2 Diabetes Trials.
Clin Pharmacol Ther
; 104(4): 699-708, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29271001
15.
Dose Unit Establishment for a New Basal Insulin Using Joint Modeling of Insulin Dose and Glycemic Response.
J Diabetes Sci Technol
; 12(1): 155-162, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28466661
16.
Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8.
Diabetes Technol Ther
; 19(8): 463-470, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28817342
17.
Quantification of Basal Insulin Peglispro and Human Insulin in Adipose Tissue Interstitial Fluid by Open-Flow Microperfusion.
Diabetes Technol Ther
; 19(5): 305-314, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28328234
18.
A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development.
Clin Pharmacokinet
; 55(7): 769-788, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26798033
19.
Simulation-Based Evaluation of Dose Titration Algorithms for U-500R Insulin by Pump in Subjects with Type 2 Diabetes.
J Diabetes Sci Technol
; 15(5): 1195-1197, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34210191
20.
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
Diabetes Care
; 39(7): 1241-9, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26681715